Arcutis Biotherapeutics, Inc. (ARQT)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS03969K1088
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Arcutis Biotherapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:55. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | 0.20 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 0.17 | 0.06 | -64.4% | Miss |
| 05 Aug 2026 16:00 | 0.05 | 0.11 | +120.0% | Beat |
| 06 May 2026 16:00 | -0.06 | -0.09 | -55.2% | Miss |
| 25 Feb 2026 16:00 | 0.09 | 0.13 | +46.8% | Beat |
| 28 Oct 2025 08:00 | -0.09 | 0.06 | +163.6% | Beat |
| 06 Aug 2025 16:00 | -0.16 | -0.13 | +17.9% | Beat |
| 06 May 2025 16:00 | -0.21 | -0.20 | +4.8% | Beat |
| 25 Feb 2025 16:00 | -0.26 | -0.09 | +66.0% | Beat |
| 06 Nov 2024 16:00 | -0.42 | -0.33 | +22.4% | Beat |
| 14 Aug 2024 16:00 | -0.53 | -0.42 | +20.8% | Beat |
| 14 May 2024 16:00 | -0.73 | -0.32 | +56.2% | Beat |
| 27 Feb 2024 07:00 | -0.80 | -0.72 | +10.0% | Beat |
| 03 Nov 2023 07:00 | -0.91 | -0.73 | +20.1% | Beat |
| 08 Aug 2023 16:00 | -1.25 | -1.16 | +7.0% | Beat |
| 09 May 2023 16:00 | -1.26 | -1.31 | -3.6% | Miss |
| 28 Feb 2023 16:00 | -1.44 | -1.18 | +17.8% | Beat |
| 08 Nov 2022 16:00 | -1.75 | -1.89 | -7.9% | Miss |
| 04 Aug 2022 16:00 | -1.42 | -1.31 | +7.8% | Beat |
| 05 May 2022 16:00 | -1.52 | -1.27 | +16.6% | Beat |
| 22 Feb 2022 16:00 | -1.54 | -1.42 | +7.9% | Beat |
| 04 Nov 2021 16:00 | -1.19 | -1.14 | +4.4% | Beat |
| 05 Aug 2021 16:00 | -0.93 | -0.84 | +9.4% | Beat |
| 04 May 2021 16:00 | -0.97 | -0.76 | +21.7% | Beat |
| 16 Feb 2021 16:00 | -0.86 | -0.79 | +8.1% | Beat |
| 05 Nov 2020 16:00 | -0.90 | -1.01 | -12.5% | Miss |
| 11 Aug 2020 16:00 | -0.84 | -0.94 | -11.5% | Miss |
| 12 May 2020 16:00 | -0.85 | -1.15 | -34.8% | Miss |
| 19 Mar 2020 16:00 | -9.21 | -6.13 | +33.4% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 376.1M | +91.3% | -16.1M | -4.3% | -0.13 | +88.8% | -16.3M |
| 2024 | 196.5M | +229.7% | -140M | -71.3% | -1.16 | +69.3% | -117.3M |
| 2023 | 59.6M | +1,517.1% | -262.1M | -439.8% | -3.78 | +33.2% | -247.5M |
| 2022 | 3.7M | — | -311.5M | -8,449.8% | -5.66 | — | -281M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 32.07 | 34.80 | 25.23 | 27.70 | -13.63% | 26,244,573 | |
| Oct 2026 | 26.10 | 33.30 | 23.37 | 32.07 | +21.34% | 50,227,700 | |
| Sep 2026 | 23.79 | 28.29 | 23.10 | 26.43 | +10.26% | 72,018,200 | |
| Aug 2026 | 26.67 | 29.24 | 23.21 | 23.97 | -10.76% | 38,340,300 | |
| Jul 2026 | 26.40 | 29.84 | 25.25 | 26.86 | +2.44% | 29,006,000 | |
| Jun 2026 | 21.37 | 28.38 | 20.48 | 26.22 | +22.18% | 39,868,000 | |
| May 2026 | 23.22 | 24.27 | 19.30 | 21.46 | -7.58% | 44,333,400 | |
| Apr 2026 | 23.85 | 25.47 | 22.13 | 23.22 | -1.44% | 21,983,400 | |
| Mar 2026 | 25.93 | 26.12 | 21.12 | 23.56 | -12.64% | 30,965,300 | |
| Feb 2026 | 25.03 | 28.80 | 24.50 | 26.97 | +6.31% | 26,858,000 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Arcutis Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 09 Nov 2026 18:42
- Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ... (opens in a new tab) GuruFocus.com · 07 Nov 2026 23:08
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab) 06 Nov 2026 21:00
- Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In? (opens in a new tab) Simply Wall St. · 06 Nov 2026 10:14
- Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch? (opens in a new tab) Investor's Business Daily · 05 Nov 2026 21:22
- TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 (opens in a new tab) Benzinga · 05 Nov 2026 16:42
- Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 13:30
- Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis (opens in a new tab) 05 Nov 2026 13:00
- Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis (opens in a new tab) Benzinga · 05 Nov 2026 09:02
- Arcutis Biotherapeutics Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 00:14
- Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates (opens in a new tab) Zacks · 04 Nov 2026 21:15
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth (opens in a new tab) Zacks · 28 Oct 2026 13:00
- Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb (opens in a new tab) Insider Monkey · 20 Oct 2026 03:37
- Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock (opens in a new tab) Simply Wall St. · 20 Oct 2026 00:21
- Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027 (opens in a new tab) TIKR · 19 Oct 2026 18:13
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 27.53 USD
- Market cap
- 3.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 7.5 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 11.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 1.2 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -1.0× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 125.14× | Weak | 30.56× |
| P/E (forward) | 25.16× | Weak | 14.16× |
| Price / book | 14.22× | Weak | 3.5× |
| Price / sales | 6.84× | Weak | 3.33× |
| EV / EBITDA | 92.3× | Weak | 11.19× |
| Free cash flow yield | 0.9% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 91.2% | Good | 54.9% |
| Operating margin | 6.9% | Weak | 5.8% |
| Net margin | 5.9% | Fair | 1.2% |
| Return on equity | 14.9% | Fair | 4.4% |
| Return on assets | 4.9% | Fair | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 367.3% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.51× | Good | 0.4× |
| Net debt / EBITDA | -3.63× | Good | 1.46× |
| Interest cover | -1.01× | Weak | 2.17× |
| Current ratio | 2.92× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow ARQT and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.